A

AFT Pharmaceuticals Ltd
NZX:AFT

Watchlist Manager
AFT Pharmaceuticals Ltd
NZX:AFT
Watchlist
Price: 2.84 NZD 1.43%
Market Cap: 297.8m NZD
Have any thoughts about
AFT Pharmaceuticals Ltd?
Write Note

AFT Pharmaceuticals Ltd
Other Long-Term Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

AFT Pharmaceuticals Ltd
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
A
AFT Pharmaceuticals Ltd
NZX:AFT
Other Long-Term Assets
NZ$1.1m
CAGR 3-Years
20%
CAGR 5-Years
10%
CAGR 10-Years
N/A
BLIS Technologies Ltd
NZX:BLT
Other Long-Term Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cannasouth Ltd
NZX:CBD
Other Long-Term Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Rua Bioscience Ltd
NZX:RUA
Other Long-Term Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
G
Greenfern Industries Ltd
NZX:GFI
Other Long-Term Assets
NZ$96.1k
CAGR 3-Years
10%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

AFT Pharmaceuticals Ltd
Glance View

Market Cap
297.8m NZD
Industry
Pharmaceuticals

AFT Pharmaceuticals Ltd. engages in the development, licensing, and distribution of medical and pharmaceutical products. The firm's segments include New Zealand, Australia, Asia and Rest of World. The firm's products include Crystaderm, Maxigesic, Coco-scalp, Maxiclear, RestoraNail and Myconail, among others. The firm's NasoSURF Nebuliser is in pilot scale production. The firm is focused on conducting clinical for Maxigesic oral dose forms. The firm is also conducting clinical trials of Maxigesic intravenous (IV). Maxigesic PE is a cold and flu variant. Its subsidiary, AFT Pharmaceuticals (AU) Pty Ltd, is engaged in distribution of pharmaceuticals in Australia. Its subsidiary, AFT Pharmaceuticals Singapore Pte Ltd, is engaged in the registration of pharmaceuticals in Singapore. Its subsidiary, AFT Pharmaceuticals (S.E. Asia) Sdn Bhd, is engaged in the distribution of pharmaceuticals in Malaysia.

AFT Intrinsic Value
4.72 NZD
Undervaluation 40%
Intrinsic Value
Price
A

See Also

What is AFT Pharmaceuticals Ltd's Other Long-Term Assets?
Other Long-Term Assets
1.1m NZD

Based on the financial report for Sep 30, 2024, AFT Pharmaceuticals Ltd's Other Long-Term Assets amounts to 1.1m NZD.

What is AFT Pharmaceuticals Ltd's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 5Y
10%

Over the last year, the Other Long-Term Assets growth was -89%. The average annual Other Long-Term Assets growth rates for AFT Pharmaceuticals Ltd have been 20% over the past three years , 10% over the past five years .

Back to Top